Publications
Publications
Show Results For
- All HBS Web
(100)
- Faculty Publications (15)
Page 1 of 15
Results
- January 2024 (Revised April 2024)
- Case
Target Malaria: Editing Mosquitoes through Gene Drives
By: Shikhar Ghosh and Shweta Bagai
Target Malaria, a non-profit research consortium, is exploring the application of CRISPR-Cas9 gene editing technology to combat malaria in Sub-Saharan Africa. Its approach uses gene drives, a revolutionary tool, to suppress the population of malaria-carrying... View Details
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details
- September 2017 (Revised February 2023)
- Case
Intermountain Healthcare: Pursuing Precision Medicine
By: Richard G. Hamermesh, Kathy E. Giusti, Robert S. Huckman and Julia Kelley
Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment... View Details
- June 2017
- Supplement
23andMe: Genetic Testing for Consumers (C)
By: John A. Quelch, Irene Lu and Emily Boudreau
- March 2014 (Revised April 2014)
- Teaching Note
23andMe: Genetic Testing for Consumers (A) and (B)
By: John A. Quelch
- January 2014 (Revised June 2014)
- Case
23andMe: Genetic Testing for Consumers (A)
By: John A. Quelch and Margaret L. Rodriguez
On November 22, 2013, the direct-to-consumer genetic testing provider, 23andMe, received a letter from the U.S. Food and Drug Administration (FDA) ordering the company to halt the sale and promotion of its genetic testing kit. The FDA stated that the product was... View Details
- January 2014 (Revised June 2014)
- Supplement
23andMe: Genetic Testing for Consumers (B)
By: John A. Quelch and Margaret L. Rodriguez
Following the FDA's letter in November 2013, which ordered 23andMe to cease sales of its DNA test kits, observers wondered how co-founder and CEO, Anne Wojcicki, would guide the company in the presence of uncertainty. View Details
- January 2014 (Revised December 2014)
- Case
GenapSys: Business Models for the Genome
By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble
GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details
- November 2009
- Case
The Explosion of Genetic Testing: Opportunities and Challenges
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay... View Details
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
- January 2009 (Revised February 2009)
- Case
Sydney IVF: Stem Cell Research
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
This case examines the strategy implementation and risk management decisions at Sydney IVF, a research-based in vitro fertilization and stem cell company based in Australia. Drs. Robert Jansen and Jock Anderson, who co-founded Sydney IVF in 1986, developed novel... View Details
- December 2008 (Revised January 2011)
- Case
Arcadia Biosciences: Seeds of Change
By: Arthur A. Daemmrich, Forest L. Reinhardt and Mary Louise Shelman
Arcadia Biosciences is an entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September 2008. The company... View Details
- October 2008
- Case
Diagnostic Genomics
By: Regina E. Herzlinger and Mark P. Allyn
Should this gene detection firm enter the business of providing tests for the detection of genetic diseases? If so, how should it prioritize the tests it could develop? View Details
- February 2008 (Revised August 2008)
- Case
EXACT Sciences Corp.: Commercializing a Diagnostic Test
This case addresses the challenges of commercializing molecular diagnostics. Along the way, it explains the technology, payment system, and the measures used to assess the value of a diagnostic test. View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details